Clinical Trials Sponsored by AstraZeneca

Total 3995 results

Fusion Pharmaceuticals Inc.

Not yet recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma
AstraZeneca

Not yet recruiting

A Randomized Trial Evaluating a mRNA VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca

Not yet recruiting

Study to Assess the Biochemical Similarity of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Heathy Participants
AstraZeneca

Not yet recruiting

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Healthy Participants

United States
AstraZeneca

Not yet recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA)

Lymphoma | Hodgkin Lymphoma | Non-Hodgkin

United States, Korea, Republic of, Australia, Italy, France
AstraZeneca

Not yet recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Canada, Spain, United States, Germany, Korea, Republic of, Taiwan, Australia, Italy, France
AstraZeneca

Not yet recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Healthy Participants

Germany, United States
AstraZeneca

Not yet recruiting

NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients (iRetroBC)

HER2-negative
AstraZeneca

Not yet recruiting

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours (PRIMROSE)

Advanced Solid Tumours That Are MTAP Deficient

United States, Spain
AstraZeneca

Not yet recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Canada, Spain, Belgium, Thailand, France, Hungary, Japan, Turkey, Korea, Republic of, Taiwan, United Kingdom, Brazil
AstraZeneca

Not yet recruiting

Non-alcoholic Steatohepatitis Registry Platform Study

NASH With Fibrosis

China
AstraZeneca

Not yet recruiting

HER-2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
AstraZeneca

Not yet recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Healthy Participants

United States
Mario Negri Institute for Pharmacological Research

Recruiting

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients (IOLANTHE)

Carcinoma, Ovarian Epithelial

Italy
Alexander B Olawaiye, MD

Not yet recruiting

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Ovarian Cancer

United States
AstraZeneca

Not yet recruiting

AZD5305 vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Finland, Germany, Italy, Spain, Belgium, Thailand, Korea, Republic of, Brazil, Malaysia, Austria, Taiwan, United Kingdom, Australia and more
AstraZeneca

Not yet recruiting

Chronic Kidney Disease Registry Platform Study

Chronic Kidney Diseases

China
AstraZeneca

Not yet recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Rheumatoid Arthritis
AstraZeneca

Not yet recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

United States, France, Italy, United Kingdom, Belgium, Canada, Vietnam, Switzerland, Germany, Korea, Republic of, Malaysia, Taiwan, Hong Kong, Australia, Hungary and more
University Hospital, Lille

Recruiting

Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness (VARI-OSCIL)

Copd

France
AstraZeneca

Not yet recruiting

A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Bil01)

Biliary Tract Cancer

Canada, Thailand, Brazil, Japan, Turkey, Taiwan, United Kingdom, Hong Kong, Germany, Australia, India
AstraZeneca

Not yet recruiting

A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma
AstraZeneca

Recruiting

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Healthy Volunteers

United States
AstraZeneca

Not yet recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Canada, Spain, United Kingdom, Taiwan, Germany, Korea, Republic of, Japan, Mexico, China, Australia, India, Singapore
TheraOp

Not yet recruiting

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC (PACCELIO)

Stage III Non-small Cell Lung Cancer | Locally Advanced | Unresectable
AstraZeneca

Not yet recruiting

A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients

Atypical Hemolytic Uremic Syndrome(aHUS)
AstraZeneca

Not yet recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

United States, Denmark, Italy, Belgium, Canada, Poland, France, Brazil, Korea, Republic of, Turkey, United Kingdom, China, Taiwan, Germany, Spain and more
AstraZeneca

Not yet recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants

Heathy Participants
AstraZeneca

Recruiting

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Chronic Kidney Disease With High Proteinuria

United Kingdom, Argentina, Italy, Spain, France, China, Germany, Vietnam, United States, Canada, Philippines, Taiwan, Norway, Mexico, Denmark and more
AstraZeneca

Not yet recruiting

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA)

Hepatocellular Carcinoma

United States
AstraZeneca

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical)

Locally Advanced Cervical Cancer

Spain, Korea, Republic of, Japan, China, Taiwan, Canada, Turkey, Peru, Brazil, Mexico, United States
AstraZeneca

Not yet recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

Canada
AstraZeneca

Recruiting

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (ATHLOS)

Chronic Obstructive Pulmonary Disease

Spain, United States, Germany, Korea, Republic of, Argentina, United Kingdom, Canada
AstraZeneca

Recruiting

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain (OSIREAL)

Non-small Cell Lung Cancer

Spain
AstraZeneca

Recruiting

The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA) (PRISMA)

Systemic Lupus Erythematosus

Russian Federation
AstraZeneca

Recruiting

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)

COVID-19, SARS-CoV-2

Russian Federation
Memorial Sloan Kettering Cancer Center

Recruiting

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Glioblastoma | Brain Cancer | Metastatic Cancer | Recurrent Glioblastoma | Leptomeningeal Metastasis

United States
University Hospital Tuebingen

Not yet recruiting

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

Renal Failure | PreDiabetes | Type2diabetes

Germany
AstraZeneca

Not yet recruiting

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

Crohn's Disease

Sweden
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
AstraZeneca

Recruiting

Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs (ERYTHRO)

Systemic Lupus Erythematosus

United Kingdom, Spain, Portugal, France, Greece, Israel, Italy
AstraZeneca

Not yet recruiting

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Hepatocellular Carcinoma (HCC)
AstraZeneca

Recruiting

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region (TREASURE)

Carcinoma, Non-Small-Cell Lung

Saudi Arabia, Kuwait, Qatar, United Arab Emirates
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (MIRANDA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Belgium, Italy, Japan, Brazil, Germany, France, Malaysia, Thailand, Greece, Hungary, Netherlands, Canada, Argentina, Ireland
German Asthma Net e.V.

Recruiting

Register Schweres Asthma - German Asthma Net e.V.

Severe Asthma

Germany
AstraZeneca

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxHTN)

Resistant Hypertension | Uncontrolled Hypertension

United States, Belgium, Germany, Italy, Spain, United Kingdom, Czechia, Thailand, Vietnam, Turkey, France, Korea, Republic of, Poland, Malaysia, Japan and more
AstraZeneca

Recruiting

PRostate Olaparib Real World Evidence Study (PROWESs)

Metastatic Castration-resistant Prostate Cancer

France
AstraZeneca

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma (HORIZON)

Asthma

United States, Spain, France, Canada, Netherlands, China, Argentina, Mexico, Korea, Republic of, Poland, Japan, Colombia, Hungary, Philippines
AstraZeneca

Not yet recruiting

Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (AJAX)

Asthma

United States, Denmark, Germany, Spain, United Kingdom, Thailand, Brazil, Malaysia, Taiwan, Argentina, France, Bulgaria, Sweden
Georgetown University

Not yet recruiting

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719)

Biliary Tract Cancer | Borderline Resectable Carcinoma

United States

X